Patents by Inventor Christopher KEVIL

Christopher KEVIL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240041917
    Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 8, 2024
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher Kevil, Gopi K. Kolluru
  • Patent number: 11883426
    Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, allicin, sugammadex, sulfanilamide, disulfiram, sulfonamide, sulfonates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: January 30, 2024
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher Kevil, Gopi K. Kolluru
  • Publication number: 20220409637
    Abstract: Therapeutics and methods of treating COVID-19 in a patient in need thereof comprising administering a pharmaceutically effective dose of a therapeutic, wherein the therapeutic contains an ACE2 externalizer, and the ACE2 externalizer is one of diminazene, diminazene aceturate, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, or prodrug thereof.
    Type: Application
    Filed: September 6, 2022
    Publication date: December 29, 2022
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Johnathan Steven ALEXANDER, Christopher KEVIL, Mansoureh BARZEGAR, Ana Maria DRAGOI
  • Publication number: 20220273702
    Abstract: Therapeutics and methods of treating COVID-19 comprising in a patient comprising administering to the patient an effective dose of a pharmacologic composition containing a first therapeutic; wherein the first therapeutic is a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment the H2S donor is one of include diallyl trisulfide (DATS), diallyl disulfide (DADS), sodium sulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, a sulfinate, a sulfoxide, a persulfide, a polysulfide, and a sulfone. According to a further embodiment the pharmacologic composition further contains a second therapeutic, wherein the second therapeutic is a nitrite, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment wherein the nitrite is an inorganic nitrite.
    Type: Application
    Filed: February 25, 2022
    Publication date: September 1, 2022
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Gopi K. Kolluru, Christopher KEVIL, Paari DOMINIC, Anthony Wayne ORR
  • Publication number: 20220169508
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 2, 2022
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Amol SOIN, Christopher KEVIL, Kyle CHAN, Anthony GIORDANO
  • Publication number: 20220163541
    Abstract: The presently disclosed invention relates to a method of diagnosing Multiple Sclerosis (MS) in a patient comprising obtaining a sample from the patient, determining a level of one or more H2S generating enzymes in the sample from the patient, and diagnosing the patient with MS when the level of the one or more H2S generating enzymes is one of at least 15% higher or lower than a control level for the one or more H2S generating enzymes, and at least 10% higher or lower than a control level for the one or more H2S generating enzymes.
    Type: Application
    Filed: November 26, 2021
    Publication date: May 26, 2022
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Johnathan Steven ALEXANDER, Christopher KEVIL, Elizabeth DISBROW, Karen Y. STOKES, J. Winny YUN, Pooja VEERAREDDY, Urska Cvek
  • Patent number: 11247902
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: February 15, 2022
    Inventors: Amol Soin, Christopher Kevil, Kyle Chan, Anthony Giordano
  • Publication number: 20220040222
    Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, dially disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.
    Type: Application
    Filed: August 9, 2021
    Publication date: February 10, 2022
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher KEVIL, Gopi K. Kolluru
  • Publication number: 20210379016
    Abstract: Therapeutics and methods of treating one of an angiotensin-converting enzyme 2 (ACE2) associated condition and an ACE2 associated pre-condition patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes either a Sigmar1 antagonist or any pharmaceutically acceptable salt, solvate, or prodrug thereof, or a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof. A method of treating coronavirus disease 2019 (COVID-19) patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof.
    Type: Application
    Filed: June 7, 2021
    Publication date: December 9, 2021
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Shenuarin BHUIYAN, Christopher KEVIL, Anthony Wayne ORR, Chowdhury S ABDULLAH, Richa Aishwarya
  • Publication number: 20210346409
    Abstract: Therapeutics and methods of treating COVID-19 in a patient in need thereof comprising administering a pharmaceutical composition containing a pharmaceutically effective dose of a therapeutic, wherein the therapeutic contains both an ACE2 externalizer and one or more ACE2 internalization preventors. Methods of treatment and pharmaceutical compositions comprising an ACE2 externalizer and one or more ACE2 internalization preventors.
    Type: Application
    Filed: May 7, 2021
    Publication date: November 11, 2021
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Johnathan Steven ALEXANDER, Christopher KEVIL, Mansoureh BARZEGAR, Ana Maria DRAGOI
  • Publication number: 20210285938
    Abstract: A method of diagnosing Alzheimer's disease and related dementias (ADRD) in a patient comprising obtaining a plasma sample from the patient; determining a level of a biochemical sulfide in the plasma sample from the subject by trapping volatilized H2S in the plasma sample using alkaline buffer with monobromobiamine, and detecting the level of biochemical sulfide in the plasma sample, the biochemical sulfide being one of acid-labile sulfide, bound sulfide, and total sulfide; and diagnosing the patient with ADRD when the level of the biochemical sulfide is at least an elevated threshold level for the biochemical sulfide.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 16, 2021
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher KEVIL, Elizabeth DISBROW, Johnathan Steven ALEXANDER, Karen Y. STOKES
  • Patent number: 10864229
    Abstract: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 15, 2020
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY
    Inventors: Christopher Kevil, David Lefer, Rakesh Patel
  • Publication number: 20200297756
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 24, 2020
    Inventors: Christopher KEVIL, Anthony GIORDANO, Douglas R. FLANAGAN, Panayiotis P. CONSTANTINIDES
  • Publication number: 20200297659
    Abstract: Methods and therapeutics for treating nitric oxide (NO) mediated conditions comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via diallyl disulfide (DADS), and the NO mediated condition includes one of inflammation, wound healing, and an infection.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Inventors: Christopher KEVIL, Sibile PARDUE
  • Patent number: 10697960
    Abstract: CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: June 30, 2020
    Assignee: BOARD OF SUPERVISORS OR LOUISANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Christopher Kevil, Robert McVie, John Glawe
  • Patent number: 10675253
    Abstract: Methods and therapeutics for treating nitric oxide (NO) mediated condition comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via DADS. Method and devices for measuring an amount of nitrite in a sample comprising obtaining a sample, adding diallyl disulfide (DADS) to the sample, measuring a post DADS amount of nitric oxide (NO) in the sample, and using the post DADS amount of NO in the sample to determine the amount of nitrite in the sample.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 9, 2020
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY
    Inventors: Christopher Kevil, Sibile Pardue
  • Publication number: 20200138966
    Abstract: The present invention is related to methods and pharmaceutical compositions comprising a Slit-2 and SDF-1? bifuncitional peptide conjugate having a Slit-2 ligand binding domain and an SDF-1? ligand binding domain.
    Type: Application
    Filed: January 29, 2018
    Publication date: May 7, 2020
    Inventors: Christopher KEVIL, John CHIDLOW, Kevin PAVLICK
  • Publication number: 20200121714
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.
    Type: Application
    Filed: June 6, 2017
    Publication date: April 23, 2020
    Inventors: Amol SOIN, Christopher KEVIL, Kyle CHAN, Anthony GIORDANO
  • Patent number: 10596188
    Abstract: A method of treating neuropathy in a subject, the method comprising identifying a subject who has neuropathy; and administering to the subject a pharmaceutical composition comprising one of inorganic nitrite and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: March 24, 2020
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Christopher Kevil
  • Publication number: 20200085861
    Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.
    Type: Application
    Filed: October 11, 2019
    Publication date: March 19, 2020
    Inventors: Christopher KEVIL, Anthony GIORDANO, Douglas R. FLANAGAN, Panayiotis P. CONSTANTINIDES